Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) Return on Sales (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Return on Sales for 12 consecutive years, with 11.03% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Return on Sales fell 910.0% year-over-year to 11.03%, compared with a TTM value of 11.03% through Nov 2024, down 951.0%, and an annual FY2024 reading of 4.66%, down 239.0% over the prior year.
  • Return on Sales was 11.03% for Q4 2024 at CNBX Pharmaceuticals, down from 4.48% in the prior quarter.
  • Across five years, Return on Sales topped out at 134.9% in Q4 2022 and bottomed at 1505.25% in Q2 2021.
  • Average Return on Sales over 5 years is 224.5%, with a median of 5.08% recorded in 2024.
  • The sharpest move saw Return on Sales tumbled -113912bps in 2021, then skyrocketed 151986bps in 2022.
  • Year by year, Return on Sales stood at 534.39% in 2020, then plummeted by -182bps to 1505.25% in 2021, then skyrocketed by 109bps to 134.9% in 2022, then tumbled by -101bps to 1.92% in 2023, then tumbled by -474bps to 11.03% in 2024.
  • Business Quant data shows Return on Sales for CNBX at 11.03% in Q4 2024, 4.48% in Q3 2024, and 3.01% in Q2 2024.